Compare Aurora Cannabis Inc (ACB) vs Stryker Corporation (SYK) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Stryker (SYK) trades at $324.73, down 0.55% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 2025 revenue of $25.12B, net income of $3.25B, and consistent earnings beats in recent quarters despite a Q1 2026 miss. Analyst consensus remains strongly positive with 72% buy ratings and a $385.30 price target, representing 19% upside potential. Recent developments include new product launches and a strategic acquisition of Amplitude Vascular Systems.

SYK presents a compelling investment case with robust profitability (63.83% gross margin, 15.2% ROE) and strong institutional support. Key risks include cybersecurity incidents impacting operations and premium valuation metrics (P/E 37.58). The stock's current position near pivot point support at $323 suggests potential for recovery toward resistance at $329, supported by positive technical indicators and strong analyst conviction.